Please login to the form below

Not currently logged in
Email:
Password:

Horizon appoints board chair

Dr Ian Gilham assumes position full-time
Horizon Ian Gilham

Horizon Discovery has appointed Dr Ian Gilham as chairman of its board of directors on a permanent basis after he spent several months as its interim chairman.

The UK-based genetic research firm will look to benefit from Dr Gilham's thirty years of industry experience, which includes his role as CEO of in vitro diagnostics company Axis-Shield.

He held this role until from 2008 to 2011, when the company was acquired by Alere.

Dr Gilham's prior experience also includes senior positions at leading pharma companies, such as GlaxoSmithKline and Abbott Labs.

Horizon's CEO Dr Darrin Disley said: “As interim chairman [Dr Gilham] has made an invaluable contribution to the growth and success of the Company and we look forward to benefitting from his guidance as Horizon continues to develop as a world-leading translational genomics organisation."

These growth prospects include a partnership with AstraZeneca to research personalised treatments in oncology.

17th January 2014

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
SEVEN STONES

Seven Stones is a creative, independent healthcare communications agency of movers and thinkers. We've been doing health differently since 1991....

Latest intelligence

BRIC markets
BRIC markets
Why these countries offer an opportunity for pharma despite a slowdown...
Obstetrics Virtual Journal Club: An Impetus Digital Customer Success Story
Our online solutions are not just for advisory boards - find out how one client leveraged the Impetus InSite Platform® for a virtual journal club....
Ludovic Helfgott
Novo Nordisk awakens its ‘Sleeping Beauty’
Biopharm emerges from troubled times to hit ‘solid growth’, says executive vice president Ludovic Helfgott...

Infographics